News Releases

Portland-Based Immunotherapy Expert Dr. Bernard A. Fox To Present at Siena, Italy Conference

Dr. Bernard A. Fox, internationally known expert in immunotherapy will meet with other cancer experts here Saturday to discuss recent advances in treatments that hold promise for improved treatments and increased survival for patients with cancer.

Read More


UbiVac Announces Positive Results of Phase II Adjuvant Clinical Trial

UbiVac, www.ubivac.com, announced the results of their randomized phase II adjuvant clinical trial in patients with definitively-treated Stage III non-small cell lung cancer (NSCLC).

Read More


Oregon Cancer Researcher to Present Findings in Europe

UbiVac CEO Dr. Bernard A. Fox will address London meeting on developing anti-cancer immunotherapeutic drugs

Read More


Immunotherapy Research Scientist Dr. Bernard Fox Receives International Award for Advancing Innovative Treatments to Cure Cancer

Washington DC—A Portland, Ore. specialist in the area of immunotherapy has been awarded the prestigious Visionary/Legacy Award by the Society for Immunotherapy of Cancer (SITC) at its 30th Anniversary Award Ceremony here. Dr.

Read More


UbiVac CEO Bernard A. Fox to Head Discussion on Immunotherapy and Translational Oncology at Providence Cancer Center

Portland, Ore.—Internationally known immunotherapy expert Bernard A. Fox, PhD, chief executive officer of UbiVac, www.ubivac.com , will be heading a panel of specialists speaking on October 20, 6:00 to 8:00 pm, at the Earle A. Chiles

Read More


UbiVac Announces Collaboration with Johnson & Johnson Innovation

UbiVac Announces Collaboration with Johnson & Johnson Innovation to Develop and Test, in Preclinical Studies, a Vaccine to Intercept Oral Cancer

PORTLAND, OR., Sept. 29, 2015 /PRNewswire/ — UbiVac, www.ubivac.com, a privately held clinical stage Immuno-Oncology

Read More


UbiVac CEO Presents at the China Center for Food and Drug International Exchange’s China Cancer Immunotherapy Workshop

Beijing, China—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, has announced that its co-founder and CEO, Bernard A. Fox, PhD, has been

Read More


Portland’s UbiVac To Detail Progress With New Cancer Therapy at International Immuno-Oncology Forum in Chicago

Portland, Ore.—UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder, Bernard A. Fox, PhD, will address the 2015 Sachs

Read More


Portland’s UbiVac Announces Two International Experts in Pharmacology to Their Advisory Board

Portland, Ore.—UbiVac, www.ubivac.com, a spinout biotechnology company of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute at Providence Portland Medical Center, has announced two internationally renowned research scientists to

Read More


Portland-based Immunotherapy Research Scientist Dr. Bernard Fox To Address Medical Conference in Tokyo

Portland, Ore—Bernard A. Fox, PhD, president and chief executive officer of Ubivac, www.ubivac.com, a spinout biotechnology company of the Robert W. Franz Cancer and Research Center within the Earle A. Chiles Research Institute at Providence

Read More


UbiVac and collaborators have three presentations at Society for Immunotherapy of Cancer meeting

Washington DC, — UbiVac, a clinical stage cancer immunotherapy company based in Portland, OR, announced additional details on UbiVac’s first-in-class autophagosome DRibble vaccine, DPV-001, in three presentations at the 28th Annual meeting of the Society

Read More


UbiVac Opens Trial of Next Generation Lung Cancer Vaccine

SYDNEY, Nov. 5, 2013 /PRNewswire/ — UbiVac, a clinical stage cancer immunotherapy company based in Portland, OR, announced the results of a Phase I clinical trial and the initiation of a Phase II clinical trial of

Read More


Oregon Bioscience company UbiVac awarded top “presenting company” honor

Beating 15 other startups, Oregon company CEOs judge UbiVac as best new bioscience company at the Oregon Bioscience Association’s annual conference, as the growing firm seeks to initiate its second clinical trial as early as

Read More


Autophagosome-enriched cancer vaccine strategy provides a novel non-genetic method to engineer leukocytes to express molecules that may augment cancer immunotherapy. (P4252)

Christopher Paustian,1Traci Hilton,2Rieneke Van De Ven,1Daniel Haley,3Chris Twitty,1Hong-Ming Hu,4Bernard Fox,1 and Sandra Aung2

1Molecular and Tumor Immunology, PPMC EACRI, Portland, OR 2UbiVac, Portland, OR 3Immunological Monitoring Lab, PPMC EACRI, Portland, OR 4Cancer Immunobiology, Earle A. Chiles

Read More